1. Sharma P , Towes A . New drugs to tackle antimicrobial resistance: analysis of EU policy options, Office of Health Economics, 2011. Available at: https://www.ohe.org/publications/new-drugs-tackle-antimicrobial-resistance-analysis-eu-policy-options. Accessed 2 May 2016.
2. Chatham House Report. Towards a new global business model for antibiotics delinking revenues from sales. Clift C , Gopinathan U , Morel C , Outterson K , Rottingen J-A , So A , eds, 2015. Available at: https://www.chathamhouse.org/publication/towards-new-global-business-model-antibiotics-delinking-revenues-sales. Accessed 2 May 2016.
3. European Commission. Action plan against the rising threats from antimicrobial resistance, 2011. Available at: http://ec.europa.eu/dgs/health_food-safety/docs/communication_amr_2011_748_en.pdf. Accessed 2 May 2016.
4. German Federal Ministry of Health. Breaking through the wall: enhancing research and development of antibiotics in science and industry, 2015. Available at: https://www.bundesgesundheitsministerium.de/fileadmin/dateien/Downloads/G/G7-Ges.Minister_2015/Qualitaetswettbewerb_Gesundheitssystem_Whitepaper_2015-10-02.pdf. Accessed 2 May 2016.
5. Organization of Economic Co-operation and Development. Antimicrobial resistance in G7 countries and beyond: economic issues, policies, and options for action, 2015. Available at: http://www.oecd.org/els/health-systems/antimicrobial-resistance.htm. Accessed 2 May 2016.